What Happened
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend that BPC-157 (as a bulk drug substance) be added to the Section 503A Bulks List, which would permit state-licensed compounding pharmacies to prepare it for patients again. This follows the FDA's September 2023 decision placing BPC-157 in Category 2 -- the category the agency uses for substances it has found present significant safety risks or lack sufficient supporting data -- which had prohibited compounding pharmacies from preparing it. FDA career staff's own briefing materials for the meeting had recommended against adding BPC-157 and the other peptides under review, citing insufficient safety and effectiveness evidence; the committee's vote went against that staff recommendation.
Why It Matters
This is a regulatory-access development, not a scientific or safety finding. A PCAC recommendation determines whether compounding pharmacies may legally prepare a substance -- it is not an FDA approval, and it does not itself establish that BPC-157 is safe or effective for any human use. The vote is advisory only; the FDA is not bound by it and must still issue its own final decision.
What the Evidence Showed
No new clinical trial, efficacy data, or safety data was presented as part of this action. The committee's discussion and vote concerned compounding-access policy for a bulk drug substance, based on the same body of evidence -- overwhelmingly preclinical/animal research, with only a small number of small, uncontrolled human pilot studies -- that FDA staff cited when recommending against the substance.
What This Does Not Establish
This vote does not establish that BPC-157 is safe or effective in humans, and it is not an FDA approval of BPC-157 for any indication. It is a non-binding recommendation; the FDA can accept or reject it, and has gone against PCAC recommendations before. It does not itself change BPC-157's compounding legality -- that requires a final FDA decision. No large, randomized, controlled human trial data for BPC-157 exists as of this event; the human evidence base remains limited to a small number of uncontrolled pilot-scale studies, in contrast to the substantially larger preclinical/animal literature.
Evidence Context
This does not change BPC-157's current MitoCore evidence grade, which already reflects a research base weighted toward preclinical/animal data with very limited controlled human evidence. This event is best understood as a regulatory-access story about compounding-pharmacy availability, not as new scientific evidence -- MitoCore's evidence-grade methodology weighs study design and human data, neither of which changed as a result of this vote.
Sources
1 source
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
FDA regulatory action